RYSTIGGO
RYSTIGGO (Rozanolixizumab-noli) is an FDA-approved monoclonal antibody infusion therapy indicated for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive. Each single-dose, preservative-free vial contains a high-concentration formulation (140 mg/mL) available in multiple doses: 280 mg, 420 mg, 560 mg, 840 mg.
Rozanolixizumab works by targeting the neonatal Fc receptor (FcRn), reducing pathogenic IgG autoantibodies responsible for neuromuscular transmission impairment. Administered subcutaneously under professional supervision, RYSTIGGO helps improve muscle strength and reduce symptoms of myasthenia gravis, offering a convenient, targeted therapy for patients with moderate to severe disease.
InfusionMed USA, located in Carrollton, Texas, supplies RYSTIGGO to hospitals, neurology clinics, and specialty infusion centers across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain integrity, proper handling, and timely delivery for all healthcare providers.
For professional use in neurology treatment centers. Administer per prescribing guidance.
Download Form